Central Pharmaceuticals Ltd. announcements
203 Dhaka Stock Exchange announcements for Central Pharmaceuticals Ltd. (CENTRALPHL) since 2013: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2023 (17).
- In response to the DSE query dated December 06, 2023, the company has informed that there is no undisclosed price sensit
In response to the DSE query dated December 06, 2023, the company has informed that there is no undisclosed price sensitive information of the company for recent unusual price hike and increase in volume of shares.
- Resumption after Record date
Trading of the shares of the company will resume on 26.11.2023.
- Suspension for Record Date
Trading of the shares of the company will remain suspended on record date i.e., 23.11.2023.
- Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle from 21.11.2023 to 22.11.2023 and trading of the shares will remain suspended on record date i.e., 23.11.2023.
- The auditor of the company has given the \"Qualified Opinion\" paragraph in the Auditor\'s Report of the company for the
The auditor of the company has given the \"Qualified Opinion\" paragraph in the Auditor\'s Report of the company for the year ended June 30, 2023. To view the details, please visit: https://www.dsebd.org/assets/pdf/Qualified\%20Opinion\%20of\%20Central\%20Pharmaceuticals\%20Limited\%20for\%20the\%20year\%20ended\%20on\%2030\%20June\%202023.pdf
- Q1 Financials
(Q1 Un-audited): EPS was Tk. (0.05) for July-September, 2023 as against Tk. (0.08) for July-September, 2022. NOCFPS was Tk. (0.00) for July-September, 2023 as against Tk. 0.00 for July-September, 2022. NAV per share was Tk. 5.54 as on September 30, 2023 and Tk. 5.59 as on June 30, 2023.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 09, 2023 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2023.
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (05.11.2023) following its corporate declaration. However, the floor price shall be applicable accordingly.
- Dividend Declaration
The Board of Directors has recommended No dividend for the year ended June 30, 2023. Date of AGM: 28.12.2023, Time: 11:30 AM, Venue: Central Pharmaceuticals Ltd. 2-A/1, South-West Darus Salam Road (2nd floor) Mirpur-1, Dhaka-1216, Bangladesh. Record date: 23.11.2023. The Company has also reported EPS of Tk. (0.37), NAV per share of Tk. 5.59 and NOCFPS of Tk. (0.00) for the year ended June 30, 2023 as against Tk. (0.57), Tk. 5.96 and Tk. (0.01) respectively for the year ended June 30, 2022.
- Reschedule of Board Meeting under LR 19(1)
The Company has further informed that, due to unavoidable circumstances, the Board meeting under LR 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, will be held on November 02, 2023 at 3:00 PM instead of October 29, 2023 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2023.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 29, 2023 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2023.
- Query Response
In response to a CSE's query dated July 11, 2023, the Company has informed that there is no undisclosed price sensitive information of the company for recent unusual price hike and increase in volume of shares.
- Q3 Financials
(Q3 Un-audited): EPS was Tk. (0.05) for January-March 2023 as against Tk. (0.08) for January-March 2022; EPS was Tk. (0.19) for July 2022-March 2023 as against Tk. (0.26) for July 2021-March 2022. NOCFPS was Tk. (0.00) for July 2022-March 2023 as against Tk. (0.00) for July 2021-March 2022. NAV per share was Tk. 5.77 as on March 31, 2023 and Tk. 6.27 as on June 30, 2022.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 30, 2023 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2023.
- Credit Rating Agency of Bangladesh Limited (CRAB) has assigned the Entity rating of the Company as \"B1\" in the long te
Credit Rating Agency of Bangladesh Limited (CRAB) has assigned the Entity rating of the Company as \"B1\" in the long term along with stable outlook based on audited financial statements up to June 30, 2022; bank liability position up to September 30, 2022 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
- Q2 Financials
(Q2 Un-audited): EPS was Tk. (0.06) for October-December 2022 as against Tk. (0.10) for October-December 2021; EPS was Tk. (0.14) for July-December 2022 as against Tk. (0.18) for July-December 2021. NOCFPS was Tk. (0.00) for July-December 2022 as against Tk. (0.00) for July-December 2021. NAV per share was Tk. 5.82 as on December 31, 2022 and Tk. 5.96 as on June 30, 2022.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 31, 2023 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2022.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.